Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) rose 4.2% on Wednesday . The company traded as high as $52.90 and last traded at $52.69, with a volume of 221,368 shares traded. The stock had previously closed at $50.55.

RARE has been the topic of a number of research reports. Canaccord Genuity reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Monday, April 4th. Zacks Investment Research lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Thursday, April 28th. Wedbush reissued an “outperform” rating and set a $92.00 target price (down from $99.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Jefferies Group reissued a “buy” rating and set a $109.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Finally, Leerink Swann reissued a “buy” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Three analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $98.09.

The company’s market cap is $2.04 billion. The stock’s 50-day moving average price is $56.27 and its 200-day moving average price is $63.75.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.29) by $0.06. During the same quarter last year, the firm earned ($0.63) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up .0% compared to the same quarter last year. Analysts expect that Ultragenyx Pharmaceutical Inc. will post ($5.84) earnings per share for the current fiscal year.

In other Ultragenyx Pharmaceutical news, insider Sunil Agarwal sold 649 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $52.68, for a total transaction of $34,189.32. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $59.95, for a total transaction of $1,199,000.00. Following the transaction, the chief executive officer now directly owns 526,704 shares in the company, valued at $31,575,904.80. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have bought and sold shares of the company. Vanguard Group Inc. increased its position in Ultragenyx Pharmaceutical by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 2,393,587 shares of the biopharmaceutical company’s stock valued at $268,512,000 after buying an additional 275,497 shares during the period. Wells Fargo & Company MN increased its position in Ultragenyx Pharmaceutical by 14.1% in the fourth quarter. Wells Fargo & Company MN now owns 1,774,736 shares of the biopharmaceutical company’s stock valued at $199,090,000 after buying an additional 219,746 shares during the period. Jennison Associates LLC increased its position in Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock valued at $84,739,000 after buying an additional 109,724 shares during the period. Brown Advisory Inc. increased its position in Ultragenyx Pharmaceutical by 4.2% in the fourth quarter. Brown Advisory Inc. now owns 114,122 shares of the biopharmaceutical company’s stock valued at $12,803,000 after buying an additional 4,584 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock valued at $6,414,000 after buying an additional 5,139 shares during the period.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.